| Company | Headquarters | Annual Revenue (USD Billion) | Year |
| Zoetis | Parsippany, New Jersey, USA | 8.5 | 2024 |
| Boehringer Ingelheim Animal Health | Ingelheim, Germany | 5.1 | 2024 |
| Merck Animal Health (MSD) | Madison, New Jersey, USA | 6.0 | 2024 |
| Elanco Animal Health | Greenfield, Indiana, USA | 4.4 | 2024 |
| Ceva Santé Animale | Libourne, France | 1.6 | 2024 |
| Virbac | Carros, France | 1.4 | 2024 |
| Vetoquinol | Lure, France | 0.5 | 2024 |
| HIPRA | Girona, Spain | 0.8 | 2024 |
| Phibro Animal Health | Teaneck, New Jersey, USA | 0.9 | 2024 |
| Indian Immunologicals Ltd | Hyderabad, India | 0.35 | 2024 |
Zoetis is the world’s largest animal health company, providing medicines, vaccines, and diagnostic products for livestock and companion animals. The company was spun off from Pfizer in 2013 and now operates independently across more than 100 countries. It leads the market with innovations in parasiticides, vaccines, and diagnostics for both veterinary clinics and large-scale livestock operations.
Simparica Trio – a broad-spectrum parasiticide for dogs.
Apoquel – treatment for allergic skin conditions in dogs.
Revalor – growth implant for cattle to improve feed efficiency.
Enhances food security through livestock health management.
Drives innovation in pet well-being through digital diagnostics.
Supports sustainable animal farming practices worldwide.
Rising regulatory scrutiny over antibiotic usage.
Supply chain disruptions affecting vaccine availability.
Increasing R&D costs in competitive markets.
Invested in alternative antimicrobial research.
Strengthened local manufacturing hubs for better distribution.
Expanded digital diagnostics and tele-vet platforms.
Strengths: Global presence, diverse portfolio, strong R&D.
Weaknesses: High dependency on top-selling drugs, regulatory pressure.
Opportunities: Expansion in emerging pet care markets, AI diagnostics.
Threats: Generic drug competition, disease outbreaks affecting demand.
In 2024, Zoetis launched an AI-driven livestock monitoring system to improve herd health analytics.
Boehringer Ingelheim Animal Health, a division of Boehringer Ingelheim, is among the top three global animal health firms. It provides vaccines, pharmaceuticals, and biologics for pets and livestock. The company is recognized for integrating innovation and sustainability into its animal health strategy.
NexGard – oral flea and tick prevention for dogs.
Ingelvac CircoFLEX – swine vaccine against circovirus.
Metacam – pain management for dogs and cats.
Promotes livestock productivity in over 150 countries.
Contributes to One Health initiatives for zoonotic disease control.
Enhances veterinary education and digital health ecosystems.
Counterfeit veterinary drugs in emerging markets.
Global logistics and regulatory disparities.
Rising cost of compliance and clinical trials.
Strengthened anti-counterfeit tracking systems.
Invested in regional vaccine manufacturing plants.
Partnered with veterinary associations for advocacy.
Strengths: Strong R&D heritage, balanced portfolio, robust supply chain.
Weaknesses: Dependence on mature product lines.
Opportunities: Growth in digital pet health and diagnostics.
Threats: Regulatory delays, global pricing pressures.
In 2024, the company launched a digital companion health monitoring platform integrated with wearable sensors.
Merck Animal Health, known as MSD Animal Health outside the U.S., is a subsidiary of Merck & Co., Inc. It develops and manufactures a broad range of veterinary pharmaceuticals, vaccines, and digital solutions for livestock and pets.
Bravecto – long-lasting flea and tick treatment.
Nobivac – comprehensive pet vaccine line.
Bovilis – cattle vaccine portfolio.
Provides animal health solutions in 150+ countries.
Pioneers livestock traceability and data-driven herd management.
Contributes to global disease eradication programs.
Disease variant evolution affecting vaccine efficacy.
Competitive pricing pressures in pet care.
Dependency on distributor networks.
Enhanced R&D for next-gen vaccines.
Strengthened direct-to-vet distribution channels.
Expanded IoT-based livestock monitoring platforms.
Strengths: Strong brand trust, innovative vaccine technology.
Weaknesses: High operational costs.
Opportunities: Expansion in aquaculture and smart farming.
Threats: Emerging biotech startups in animal vaccines.
In 2025, MSD launched a blockchain-based livestock tracking platform to ensure transparency in meat production.
Elanco, spun off from Eli Lilly, focuses on improving the health of animals through products for pets and livestock. It merged with Bayer Animal Health in 2020, expanding its global footprint and product range.
Seresto – flea and tick collar.
Advantix – parasitic protection for dogs.
Rumensin – feed additive for cattle.
Enhances pet care affordability through wide retail distribution.
Promotes sustainable livestock farming practices.
Provides disease prevention in developing economies.
Integration challenges post-Bayer acquisition.
Increasing debt levels affecting R&D investment.
Environmental concerns around feed additives.
Streamlined portfolio to focus on high-value brands.
Initiated cost-reduction and restructuring programs.
Invested in greener manufacturing technologies.
Strengths: Broad portfolio, strong pet and livestock base.
Weaknesses: High leverage, integration risks.
Opportunities: Companion animal market growth, emerging economies.
Threats: Generic competition, tightening EU regulations.
In 2024, Elanco announced a new digital parasite protection monitoring app for pets.
Ceva is a French multinational animal health company offering vaccines, pharmaceuticals, and preventive care products. It is a private, rapidly growing company with strong expertise in poultry and swine vaccines.
Vectormune ND – poultry vaccine against Newcastle disease.
Cevac IBD L – immunization against infectious bursal disease.
Feliway – pheromone-based anxiety management for cats.
Plays a key role in global poultry health improvement.
Expands veterinary solutions in over 110 countries.
Contributes to reducing antibiotic use through prevention-based care.
Rising input and logistics costs.
Competition from multinational peers.
Regional disparities in veterinary infrastructure.
Built regional vaccine production hubs.
Invested in R&D for next-gen biotherapeutics.
Enhanced collaboration with governments on disease control.
Strengths: Innovation in poultry vaccines, flexible R&D.
Weaknesses: Smaller scale compared to top 3 players.
Opportunities: Expansion in pet behavior therapy and biologics.
Threats: Price competition, regulatory delays.
In 2025, Ceva launched a next-gen poultry vector vaccine combining two disease protections in one dose.
Virbac is a French animal health company specializing in vaccines and pharmaceuticals for companion animals and livestock. Founded in 1968, it has a strong presence in Europe, Latin America, and Asia-Pacific.
Effitix – external parasite control for dogs.
Iverhart Max – heartworm prevention.
CaniLeish – canine leishmaniasis vaccine.
Expands affordable veterinary solutions in emerging markets.
Promotes responsible antibiotic use and alternative therapies.
Supports education programs for veterinarians globally.
Currency fluctuations affecting export revenue.
Competitive pressure from larger players.
Dependence on mature product lines.
Increased localization of production.
Launched new vaccine formulations.
Enhanced e-commerce and direct vet distribution channels.
Strengths: Broad species coverage, innovation in niche vaccines.
Weaknesses: Moderate R&D budget vs. peers.
Opportunities: Expanding pet care demand in Asia.
Threats: Market consolidation among bigger firms.
In 2025, Virbac launched a new oral parasiticide for cats with extended protection duration.
Vetoquinol is a French veterinary pharmaceutical company known for its focus on pets and livestock. It operates in over 100 countries and emphasizes innovation in anti-infectives and pain management.
Marbocyl – antibiotic for dogs and cats.
Flexadin – joint health supplement.
Clavaseptin – broad-spectrum antibiotic.
Strengthens veterinary capabilities globally through partnerships.
Focuses on sustainable animal health practices.
Provides therapeutic options for under-served species.
Growing scrutiny over antibiotic stewardship.
Competition from nutraceutical-based alternatives.
Limited penetration in North America.
Invested in non-antibiotic therapeutics.
Expanded into companion animal supplements.
Strengthened marketing alliances in the U.S. and Canada.
Strengths: Strong brand reputation, innovation focus.
Weaknesses: Limited scale versus top-tier competitors.
Opportunities: Growth in animal nutraceuticals.
Threats: Regulatory changes in antimicrobial policies.
In 2024, Vetoquinol launched a probiotic-based product line for companion animal gut health.
HIPRA is a Spanish biopharmaceutical company dedicated to the research, production, and marketing of vaccines for animals and humans. It is globally known for its poultry, swine, and bovine vaccine portfolios.
Hiprasuin – swine reproductive vaccine.
Hiprabovis – bovine respiratory vaccine.
Eryseng – dual vaccine for swine erysipelas and parvovirus.
Enhances food safety through advanced livestock immunization.
Strong R&D footprint in Europe and Latin America.
Supports veterinary training programs worldwide.
Need for faster regulatory approvals.
Increasing R&D expenses in biotechnology.
Limited diversification beyond vaccines.
Diversified into human vaccines (COVID-19 initiative).
Enhanced collaboration with global veterinary institutions.
Expanded automated production facilities.
Strengths: Specialized vaccine expertise, innovation pipeline.
Weaknesses: Narrow product portfolio.
Opportunities: Human vaccine integration, digital diagnostics.
Threats: Competitive R&D races, supply chain costs.
In 2025, HIPRA inaugurated a new biotechnology R&D center in Girona focused on next-generation vaccines.
Phibro Animal Health is a U.S.-based company focusing on animal health and nutrition. It provides vaccines, medicated feed additives, and nutritional supplements for livestock.
Omnigen-AF – stress management product for cattle.
V-MAX – antibiotic feed additive.
Animate – dairy cow nutritional supplement.
Enhances livestock productivity and food quality globally.
Active in over 80 countries with a strong North American base.
Promotes antibiotic alternatives and sustainable solutions.
Decline in antibiotic additive demand.
Margin pressure due to raw material costs.
Intense market competition.
Focused R&D on nutritional and vaccine-based products.
Streamlined global operations for efficiency.
Introduced antibiotic-free solutions.
Strengths: Established global network, diverse portfolio.
Weaknesses: Heavy reliance on livestock sector.
Opportunities: Expansion into aquaculture and probiotics.
Threats: Regulatory shifts against medicated feeds.
In 2024, Phibro launched a new probiotic line targeting gut health in poultry.
Indian Immunologicals Ltd, a subsidiary of the National Dairy Development Board, is one of India’s leading vaccine manufacturers for animals and humans. It is a major global supplier of foot-and-mouth disease vaccines.
Raksha FMD – foot-and-mouth disease vaccine.
Raksha Blu – bluetongue vaccine.
Vaxsafe – rabies vaccine for animals.
Strengthens livestock health in developing countries.
Exports vaccines to over 60 nations.
Supports rural vaccination programs to boost farmer income.
Infrastructure limitations in rural distribution.
Pricing pressures in domestic tenders.
Need for modernization in production lines.
Expanded capacity with a new vaccine manufacturing facility.
Adopted cold chain innovations for rural logistics.
Increased R&D collaboration with global partners.
Strengths: Strong public trust, cost-effective vaccines.
Weaknesses: Lower margins compared to global peers.
Opportunities: Export expansion, human-animal vaccine synergy.
Threats: Global price competition, disease unpredictability.
In 2024, IIL launched a thermostable FMD vaccine for improved rural access.
The veterinary vaccines market size is calculated at US$ 9.47 billion in 2024, grew to US$ 10.04 billion in 2025, and is projected to reach around US$ 17.07 billion by 2034. The market is expanding at a CAGR of 6.07% between 2025 and 2034.
To bring public health and animal care into alignment, veterinary vaccination campaigns are being coordinated under the One Health framework to combat zoonotic threats such as bird flu. Increased worries about the human transmission of avian influenza have prompted governments and industry participants to expedite poultry vaccine testing. By combining environmental animal and human health strategies, veterinary vaccinations serve as a vital line of defense against pandemics. Increasing international cooperation in immunization and surveillance underscores the growing significance of such initiatives for public health and food security.
Pilot studies of avian flu vaccination in poultry demonstrate high protection, opening the door for wider commercial operations adoption. For regulatory approval and farmer confidence, field trials are essential for validating vaccine performance under actual farming conditions. For illnesses like avian flu that are hazardous to both agriculture and public health, successful demonstrations are especially crucial. It is anticipated that widespread distribution of avian flu vaccines will become commonplace as more nations fund these studies, improving biosecurity in the production of poultry.
In the veterinary vaccines industry, research and development (R&D) is concentrated on creating new vaccines for companion and livestock animals, enhancing antigen stability, and developing delivery systems like oral and intranasal formulations. Additionally, efforts are focused on next-generation technologies to improve safety and efficacy, such as vector-based vaccines, mRNA, and recombinant DNA.
Key players include: Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, and Elanco Animal Health.
Clinical trials evaluate vaccine safety, dosage optimization, and immune response across different animal species. Regulatory bodies such as the USDA (United States Department of Agriculture), EMA (European Medicines Agency), and CDSCO (India) oversee approval processes to ensure product safety, effectiveness, and compliance with veterinary health standards.
Key players include: Ceva Santé Animale, Virbac, Indian Immunologicals Ltd., HIPRA.
In the veterinary vaccines market, patient support focuses on helping veterinarians and animal owners make sure that both livestock and companion animals are properly informed about vaccination programs. Reminders for vaccinations, electronic record-keeping platforms, and helplines for farmers and pet owners are among the services offered. To gain trust, businesses also promote certifications like ISO GMP, Halal, and Organic, and offer instructional materials on preventing zoonotic diseases. Through outreach initiatives, emphasis is placed on enhancing accessibility in rural areas to guarantee that the advantages of preventive care are felt by a larger animal population.
Key players include: Zoetis Inc., Boehringer Ingelheim, Virbac, Elanco Animal Health, and Ceva Santé Animale
In February 2025, Elanco Animal Health entered an agreement with Medgene to commercialize a highly pathogenic avian influenza vaccine for dairy cattle. The CEO of Elanco remarked, “Elanco is pleased to partner with Medgene and believes this product will become part of a routine vaccination protocol for the U.S. dairy industry.”
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
